Does cyclin E and p57

Tumay Ozgur, Ahmet Taner Sumbul, Mehmet Yaldız, Muhyittin Temiz, Abdurrahman Akdağ

Abstract read

In one paragraph

Article in International journal of clinical and experimental pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact, top 72% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Tumay OzgurDepartment of Pathology, School of Medicine, Mustafa Kemal University Serinyol-Hatay, Turkey.

Ahmet Taner SumbulDepartment of Medical Oncology, Adana Başkent University Yüreğir-Adana, Turkey.

Mehmet YaldızDepartment of Pathology, School of Medicine, Mersin University Yenişehir-Mersin, Turkey.

Muhyittin TemizDepartment of General Surgery, School of Medicine, Mustafa Kemal University Serinyol-Hatay, Turkey.

Abdurrahman AkdağDepartment of Medical Laboratory Techniques, Vocational School of Health Sciences, Harran University Şanlıurfa, Turkey.

Mustafa Kemal University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionColorectal cancer is still one of the main causes of cancer death in the world. There is a continous need for novel biomarkers for diagnose, treatment modalities and follow-up. Cyclin E and p57 MATERIALS AND

methodsIn a retrospective setting, primary colorectal adenocarcinoma cases examined in Mustafa Kemal University, School of Medicine, Pathology Department between 2008-2015 were reviewed. Immunohistochemical expressions of cyclin E and p57

resultsThere were no statistically significant difference between two groups both in cyclin E and p57

conclusionsImmunohistochemical studies of cyclin E and p57

Indexed as

colorectal adenocarcinomaCyclin Eimmunohistochemistryp57KIP2

Identifiers

PMID31949774

PMCPMC6962821

OpenAlexW3028357876

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.